{"entity":{"id":"nct03865082","kind":"trial","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","aka":[],"tldr":"A phase 2 trial of Nivolumab and Ipilimumab in advanced solid tumours, run by Idera Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) is a phase 2 interventional study registered as NCT03865082 by Idera Pharmaceuticals, Inc., with 30 participants enrolled, started 2019-10-29 and due to reach its primary completion in 2022-03. Interventions recorded: Tilsotolimod, Nivolumab and Ipilimumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03865082","url":"https://clinicaltrials.gov/study/NCT03865082"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["idera-pharmaceuticals","bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03865082","phase":"2","setting":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors","sponsor":"Idera Pharmaceuticals, Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct03865082/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/"}]}}